Tag Archives: EHA

June, 2018

15 June
Novartis Survey Uncovers Real-World Impact of Immune Thrombocytopenia on Patients’ Quality of Life

Basel, June 15, 2018 – Many patients with the rare blood disorder immune thrombocytopenia (ITP) find the disease has a negative impact on their everyday quality of life, according to interim results of a Novartis survey, called I-WISh, presented today at the 23rd Congress of the European Hematology Association (EHA) in Stockholm, Sweden …
Share

10 June
Amgen’s Blincyto Improved Overall Survival in Patients with B-Cell Precursor ALL

THOUSAND OAKS, Calif., June 10, 2016 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced new data from a prespecified interim analysis of the Phase 3 TOWER study, in which BLINCYTO® (blinatumomab) demonstrated an almost two-fold increase in median overall survival (OS) compared to standard of care (SOC). The randomized, open-label TOWER …
Share

19 October
Pfizer’s ALL Drug Receives Breakthrough Therapy Designation

Pfizer Inc. today announced that investigational antibody-drug conjugate (ADC) inotuzumab ozogamicin received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for acute lymphoblastic leukemia (ALL). The Breakthrough Therapy designation was based on the results of the Phase 3 INO-VATE ALL trial, which enrolled 326 adult patients with …
Share